# OnCo record talquetamab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/talquetamab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "talquetamab" ;
  schema:name "Talquetamab"@en ;
  schema:description "Talquetamab is the first drug against GPRC5D, a second myeloma target used after BCMA therapies stop working; taste and skin side effects are its signature."@en ;
  schema:url <https://onco.cc/drugs/talquetamab/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Talquetamab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q116777032> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Talquetamab> ;
  onco:status "approved" ;
  onco:modality "Bispecific T-cell engager (GPRC5D×CD3)" ;
  schema:alternateName "Talvey" ;
  onco:approval "US 2023: Relapsed/refractory myeloma after ≥4 lines (accelerated)" ;
  onco:acceleratedApproval "US 2023-08-09: Adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/myeloma-relapsed-refractory/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/> ;
  onco:targets <https://onco.cc/targets/gprc5d/>, <https://onco.cc/targets/cd3/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> ;
  onco:trials <https://onco.cc/trials/monumental-1/>, <https://onco.cc/trials/nct06208150/>, <https://onco.cc/trials/nct05552222/>, <https://onco.cc/trials/nct05455320/>, <https://onco.cc/trials/nct06550895/>, <https://onco.cc/trials/nct04586426/>, <https://onco.cc/trials/nct06577025/>, <https://onco.cc/trials/nct06500884/> .